title: Translational Research Working Group developmental pathway for immune response modifiers.
abstract: The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Cheever
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schlom
authors.forename: Louis M
authors.initials: LM
authors.lastname: Weiner
authors.forename: H Kim
authors.initials: HK
authors.lastname: Lyerly
authors.forename: Mary L
authors.initials: ML
authors.lastname: Disis
authors.forename: Addison
authors.initials: A
authors.lastname: Greenwood
authors.forename: Oren
authors.initials: O
authors.lastname: Grad
authors.forename: William G
authors.initials: WG
authors.lastname: Nelson
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000628:therapy*; D009934:Organization and Administration; D016730:Program Development; D012985:Software Design; D014481:United States
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors
references.citation: J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601
references.pmid: 9362157
references.citation: Blood. 1994 Oct 1;84(7):2221-8
references.pmid: 7919339
references.citation: J Clin Oncol. 1997 Nov;15(11):3363-7
references.pmid: 9363867
references.citation: Crit Rev Immunol. 2007;27(5):451-62
references.pmid: 18197807
references.citation: N Engl J Med. 2008 Jun 19;358(25):2704-15
references.pmid: 18565863
references.citation: Clin Cancer Res. 1999 Jun;5(6):1289-97
references.pmid: 10389911
references.citation: Clin Cancer Res. 2005 Jun 15;11(12):4430-6
references.pmid: 15958627
references.citation: Biol Blood Marrow Transplant. 2005 Jan;11(1):23-34
references.pmid: 15625541
references.citation: Adv Immunol. 2006;90:297-339
references.pmid: 16730267
references.citation: Exp Biol Med (Maywood). 2008 May;233(5):522-34
references.pmid: 18375829
references.citation: Clin Cancer Res. 2008 Sep 15;14(18):5664-71
references.pmid: 18612047
references.citation: Nat Rev Cancer. 2005 May;5(5):397-405
references.pmid: 15864281
references.citation: J Immunol. 1996 May 1;156(9):3151-8
references.pmid: 8617935
references.citation: Immunol Rev. 2008 Apr;222:357-68
references.pmid: 18364014
references.citation: Update Cancer Ther. 2007 Mar;2(1):33-39
references.pmid: 17948067
references.citation: Cancer Res. 1969 Apr;29(4):848-54
references.pmid: 4887203
references.citation: J Clin Oncol. 2004 May 15;22(10):1916-25
references.pmid: 15143085
references.citation: J Clin Oncol. 2002 Jun 1;20(11):2624-32
references.pmid: 12039923
references.citation: Cancer Res. 1981 Apr;41(4):1358-62
references.pmid: 7011535